LuciTepo 225 mg Tablets contain tepotinib which is a targeted therapy used in the treatment of non small cell lung cancer with MET gene alterations. It helps slow tumor growth and supports better disease management in patients who are not suitable for conventional treatments. This medicine is prescribed by oncology specialists and is widely used in the United Kingdom, United States, Australia, Singapore and Philippines. It offers a precision based approach that focuses on specific cancer pathways and helps improve treatment outcomes with manageable safety profiles. Active Ingredient Tepotinib is a MET inhibitor that blocks abnormal signaling caused by MET gene mutations. It belongs to targeted cancer therapy drugs that act on specific molecular pathways involved in tumor growth. Uses of LuciTepo 225 mg Tablets • Treatment of non small cell lung cancer • Management of MET altered cancers • Support for targeted oncology therapy • Control of tumor progression How LuciTepo 225 mg Tablets Works Tepotinib works by inhibiting the MET receptor tyrosine kinase which is responsible for cancer cell growth and survival in certain tumors. By blocking this pathway the medicine reduces abnormal cell proliferation and helps control tumor spread. This targeted action allows better disease management. How to Use LuciTepo 225 mg Tablets 1. Take the tablet with food as directed by your doctor. 2. Swallow whole with water without crushing. 3. Follow the prescribed dosage schedule strictly. Possible Side Effects • Swelling in limbs • Nausea • Fatigue • Diarrhea Precautions • Monitor liver function regularly • Inform your doctor about any lung issues • Avoid use during pregnancy Safety Information Use only under medical supervision. Regular monitoring is essential to track response and detect side effects early for safe treatment. Storage • Store at room temperature below 25°C • Protect from moisture • Keep out of reach of children

LuciPirto 50 mg Tablets contain pirtobrutinib which is a targeted cancer therapy used in the treatment of certain blood cancers such as mantle cell lymphoma. It helps slow down abnormal cell growth and supports disease control in patients who have received prior treatments. This medicine is prescribed under specialist supervision and is widely used across healthcare systems in the United Kingdom, United States, Australia, Singapore and Philippines. It plays an important role in modern oncology care by offering a more targeted approach with improved tolerability compared to traditional chemotherapy options. Active Ingredient Pirtobrutinib is a Bruton's tyrosine kinase inhibitor. It works by blocking signals that promote cancer cell growth. This targeted mechanism allows it to act specifically on malignant cells while reducing damage to healthy cells. Uses of LuciPirto 50 mg Tablets • Treatment of mantle cell lymphoma • Management of relapsed or refractory blood cancers • Support for targeted cancer therapy • Control of abnormal B cell growth How LuciPirto 50 mg Tablets Works Pirtobrutinib inhibits Bruton's tyrosine kinase which is essential for the survival and proliferation of B cells. By blocking this enzyme the medicine disrupts signaling pathways that cancer cells rely on to grow and divide. This leads to reduced tumor progression and improved disease control. How to Use LuciPirto 50 mg Tablets 1. Take the tablet orally with water as prescribed by your doctor. 2. Maintain a consistent dosing schedule for best results. 3. Do not crush or chew the tablet unless advised. Possible Side Effects • Fatigue • Diarrhea • Nausea • Mild infections Precautions • Use under strict medical supervision • Inform your doctor about liver or kidney conditions • Avoid during pregnancy unless advised Safety Information Always follow your healthcare provider’s instructions. Do not adjust dosage without medical advice. Regular monitoring is required to ensure safe and effective treatment. Storage • Store below 25°C in a dry place • Keep away from direct sunlight • Keep out of reach of children

LuciPona 45 mg is a higher strength formulation of ponatinib used in the treatment of advanced or resistant leukemia. It is prescribed when lower doses or other treatments are not sufficient. This medicine is part of specialized oncology care in the United Kingdom, United States, Australia, Singapore and Philippines. LuciPona 45 mg helps slow disease progression and manage symptoms effectively when used under expert medical guidance. Active Ingredient Ponatinib is a potent tyrosine kinase inhibitor that targets multiple signaling pathways involved in cancer growth. It is especially effective against resistant mutations. Uses of LuciPona 45 mg • Treatment of advanced leukemia • Management of resistant cancer cases • Relief from disease symptoms • Support for targeted therapy How LuciPona 45 mg Works Ponatinib blocks abnormal kinase activity in cancer cells preventing their growth and survival. This leads to reduced tumor burden and improved disease control. How to Use LuciPona 45 mg 1. Take exactly as prescribed 2. Swallow whole with water 3. Do not change dose without advice Possible Side Effects • High blood pressure • Fatigue • Nausea • Skin rash Precautions • Regular cardiovascular monitoring required • Inform doctor about liver conditions • Avoid use during pregnancy Safety Information Use only under specialist supervision. Close monitoring is essential due to potential serious side effects. Storage • Store in a cool dry place • Protect from moisture • Keep out of reach of children